Loading company…
XGene Pharmaceutical develops small-molecule drugs for pain, infectious disease and tumors, based in Shanghai.
Based in Shanghai, China and established in 2015, XGene Pharmaceutical Inc., trading as XGene Pharmaceutical, develops small-molecule drugs and combination therapies for pain, infectious diseases and tumors. Its core product, XG005, is a non-opioid analgesic, and the company plans to use the funding for a Phase III acute pain trial in the United States. In July 2026 it raised CNY 250 million in Series D funding co-led by Efung Capital and GTJA Investment Group, with participation from Winfund Investment, Real Capital Global and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in